Leerink Partnrs Issues Negative Estimate for UTHR Earnings

United Therapeutics Co. (NASDAQ:UTHR) – Leerink Partnrs reduced their Q4 2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will earn $6.90 per share for the quarter, down from their prior estimate of $7.77. The consensus estimate for United Therapeutics’ current full-year earnings is $25.21 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2025 earnings at $7.85 EPS.

Several other research analysts have also issued reports on UTHR. The Goldman Sachs Group lifted their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. HC Wainwright lifted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus upped their target price on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $382.08.

United Therapeutics Price Performance

NASDAQ UTHR opened at $370.74 on Thursday. United Therapeutics has a 12 month low of $211.61 and a 12 month high of $417.82. The company has a market capitalization of $16.55 billion, a P/E ratio of 16.28, a PEG ratio of 0.92 and a beta of 0.57. The company’s 50 day simple moving average is $361.99 and its 200 day simple moving average is $358.32.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,485,785.60. The trade was a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 121,864 shares of company stock worth $44,516,965. 11.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of UTHR. SG Americas Securities LLC boosted its holdings in United Therapeutics by 66.1% in the third quarter. SG Americas Securities LLC now owns 1,493 shares of the biotechnology company’s stock worth $535,000 after purchasing an additional 594 shares in the last quarter. CWM LLC lifted its position in shares of United Therapeutics by 108.3% in the third quarter. CWM LLC now owns 4,006 shares of the biotechnology company’s stock worth $1,436,000 after buying an additional 2,083 shares during the last quarter. Ritholtz Wealth Management boosted its stake in shares of United Therapeutics by 14.3% during the 3rd quarter. Ritholtz Wealth Management now owns 839 shares of the biotechnology company’s stock worth $301,000 after acquiring an additional 105 shares in the last quarter. Creative Planning increased its holdings in shares of United Therapeutics by 8.9% during the 3rd quarter. Creative Planning now owns 3,935 shares of the biotechnology company’s stock valued at $1,410,000 after acquiring an additional 322 shares during the last quarter. Finally, Kapitalo Investimentos Ltda increased its holdings in shares of United Therapeutics by 69.4% during the 3rd quarter. Kapitalo Investimentos Ltda now owns 1,470 shares of the biotechnology company’s stock valued at $527,000 after acquiring an additional 602 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.